Q4 2024 Devyser Diagnostics AB Earnings Call Transcript
Key Points
- Devyser Diagnostics AB (FRA:OL0) reported its first profitable quarter as a public company in Q4 2024.
- Revenue for Q4 2024 increased by 41.5% compared to the same quarter last year, reaching SEK 64.2 million.
- The company has a strong partnership with Thermo Fisher, which resulted in the largest order in the company's history during Q4.
- Devyser's gross margins improved to close to 85% in Q4, indicating strong operational efficiency.
- The company has a clear strategy to focus on two customer segments: clinical genetics labs and transplantation labs, aiming to become a leading partner in these fields.
- Direct sales decreased as a result of transitioning customers to Thermo Fisher, impacting revenue distribution.
- APAC region experienced a small decline in growth, contrasting with other regions' performance.
- The company had to make a provision for an Italian payback fee, which negatively impacted EBIT.
- Inventory buildup from Thermo Fisher in Q4 may affect purchasing patterns in early 2025.
- Capitalized R&D expenses nearly doubled year-over-year, which could impact short-term profitability.
Good day and welcome to the Devyser Q4 2024 earnings call.
I'm Fredrik Dahl, the acting CEO of Devyser, and would like to thank you everyone for joining our call today.
On the call today, we have in addition to myself, also our CFO Sabina Berlin, and our Chief Commercial Officer Theis Kipling.
Since this is my first earnings call for Devyser, I will start with a short introduction on who I am and my background. I will then review our updated strategy before handing over to Sabina for a review of our financial results in Q4 2024, and then to Theis for an update on our commercial activities.
I have been a board member of the Devyser since 2021 and is the acting CEO since January 16th. I have a PhD in molecular medicine from Uppsala University and carried out the post-doc, at Stanford in DNA technology development.
After my studies at Stanford, I worked in start-up scene in Silicon Valley in NextGen sequencing, and have co-founded both Halo genomics and Vanity diagnostics that we sold to Adulant and Perkin
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
